Inclusion Criteria:

- Patient suffering from an upper aerodigestive tract carcinoma treated by radiotherapy
alone or radiotherapy associated with a concomitant platine-salts-based chemotherapy
;

- Patient suffering of an upper aerodigestive tract carcinoma without entrance or
located in the oral cavity, in the oropharynx or in the rhinopharynx ;

- Patient age of 18 years old or higher ;

- Writing informed consent to participate to the trial ;

- Patient affiliated to the French social security system.

Exclusion Criteria:

- Treatment by non-standard fragmentation (concentrate irradiation)

- Carcinoma located in the hypopharynx or in the larynx ;

- Known hypersensitivity to heparinoids ;

- Patient who already benefited from a radiotherapy treatment ;

- Patient who already benefited from a chemotherapy treatment. Patients who benefited
from neoadjuvant chemotherapy as part of their upper aerodigestive tract carcinoma
care, may be included if it was held at least 4 weeks before the inclusion visit ;

- Patient participating to another biomedical research ;

- Pregnant woman, breastfeeding woman, parturient or likely to be ;

- Patient deprived of freedom, under supervision or guardianship ;

- Patient unable to attend to scheduled medical monitoring due to geographical, social
or mental reasons